An advantage of CRS3123 compared with other treatments is its narrow spectrum, which targets C. difficile bacteria and stops toxin production while minimally affecting other microbes in the gut.

Boulder, Colorado-based biotech Crestone is going after C. diff with a new antimicrobial, CRS3123. In a phase 2 study, the company reports that its drug cured 28 of 29 patients within 12 days ...

Dr. Thomas Louie of University of Calgary, Canada, principal investigator for this study, stated: “Treatment of C. difficile infection remains in urgent need of agents that spare normal gut ...

And yet, 68 percent of the global population isn't getting enough of it, at least from diet. More From Newsweek ... (and 71 percent of your daily vitamin C intake while you're at it).

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

In a phase-one human clinical trial, a University of Houston pharmacist researcher has demonstrated that a newer generation tetracycline antibiotic, called Omadacycline, may be a promising tool in ...